Tremelimumab (Imjudo)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is established

Diseases for which it is used

History of changes in FDA indication

  • 10/21/2022: Approved in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). (Based on HIMALAYA)
  • 11/10/2022: Approved in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (Based on POSEIDON)

Also known as

  • Code name: CP-675, CP-675206
  • Generic name: ticilimumab
  • Brand name: Imjudo